Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31447986 | 1.00 | APLNR (0.42) | APLNRAOC3TRPV3NTRK1KCNH2 | |
| SCHEMBL4025184 | 0.84 | APLNR (0.43) | APLNRAOC3NTRK1KCNH2JAK2 | |
| Hydrochloric Acid SCHEMBL4974167 | 0.83 | APLNR (0.42) | APLNRAOC3KCNH2JAK2HRH1 | |
| SCHEMBL26621160 | 0.79 | APLNR (0.37) | APLNRTRPV3NTRK1KCNH2KMO | |
| SCHEMBL3946064 | 0.77 | CYP1A2 (0.45) | APLNRAOC3KMO | |
| SCHEMBL4023229 | 0.77 | APLNR (0.41) | APLNRKMO | |
| SCHEMBL3937910 | 0.77 | AOC3 (0.32) | AOC3 | |
| SCHEMBL25581873 | 0.77 | APLNR (0.49) | APLNRKCNH2JAK2HRH1KMO | |
| SCHEMBL13365274 | 0.77 | APLNR (0.49) | APLNRTRPV3NTRK1KCNH2ESR1 | |
| SCHEMBL18245918 | 0.76 | APLNR (0.50) | APLNRAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-08-21 | — | — | US | disclosed |
| EP-4514794-A1 | FGFR2 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023212535-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212535-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009007753-A2 | 4- (3-AMINOPYRAZOLE) -PYRIMIDINE DERIVATIVEE AND THEIR USE AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | FGFR2, FGFR1, FGFR3 | APLNR 1256/4885AOC3 4610/4885TRPV3 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.